康宁杰瑞制药(09966.HK)于美国AACR年会公布两项临床前研究成果

阿斯达克财经
30 Apr

康宁杰瑞制药-B(09966.HK) 公布,JSKN021及JSKN022临床前研究的最新成果,已于今年4月25至30日举行的2025年AACR年会的壁报展示期间公布。
据介绍,JSKN021是一款全球首创的双抗双载荷偶联药物,通过精确调控双抗结合亲和力设计,在应对肿瘤异质性的同时最大限度地降低靶向脱瘤毒性,具有增强的稳定性和更优的均一性;至于JSKN022是靶向PD-L1及αVβ6的全球首创多功能ADC,利用糖基定点偶联技术,实现位点特异性的载荷偶联,通过可裂解连接子递送专利载荷TOPO1抑制剂Alphatecan,进而提升稳定性与疗效。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-04-29 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10